Doseology Appoints Timothy Corkum as President & COO to Drive Strategic Expansion into the Stimulant Pouch Market
Kelowna, BC – June 17, 2025 – Doseology Sciences Inc. (CSE: MOOD | PINK: DOSEF | FSE: VU70) (“Doseology” or the “Company”), an innovator in precision-formulated oral stimulants, is pleased to announce the appointment of Mr. Timothy Corkum as President and Chief Operating Officer, effective immediately.
Mr. Corkum brings over 20 years of executive leadership experience across the global consumer packaged goods (CPG) and nicotine sectors. His prior roles include senior positions at Philip Morris International, President of JUUL Labs Canada, and Chief Revenue Officer at TAAT Global Alternatives, where he oversaw retail expansion and operational planning across regulated categories.
In his new role at Doseology, Mr. Corkum will lead commercial operations, innovation strategy, and product rollout as the Company executes its dual-market strategy—expanding into the high-growth nicotine pouch segment and the emerging functional pouch category, powered by caffeine, nootropics, and clean-label actives.
“Mr. Corkum’s leadership experience across highly regulated, performance-driven markets aligns perfectly with Doseology’s long-term vision,” said Chris Jackson, CEO of Doseology. “His operational and commercial expertise will strengthen our position as we expand into the stimulant pouch market and other oral delivery systems designed for today’s modern, health-conscious consumer.”
“I’m excited to join Doseology at such a pivotal stage,” said Timothy Corkum, President & COO of Doseology. “The company is committed to innovation, disciplined execution, and staying closely aligned with evolving consumer demand. We’re focused on building a scalable business with long-term value potential.”
Positioned for Growth in the Better-for-You Oral Stimulant Pouch Market
Doseology is one of the first Canadian small-cap public companies to focus on the emerging better-for-you stimulant pouch market, which integrates nicotine alternatives, clean energy, and functional wellness ingredients into convenient, discreet formats.
Doseology’s broader strategy includes development of oral stimulant IP and formulation technologies that may be adapted for athletic, clinical, and professional applications.
The Company currently maintains a national presence in Canada through its functional mushroom line, setting the stage for broader product expansion and introduction across all channels of distribution, including retail, direct-to-consumer (DTC), and health and specialty networks.
About Timothy Corkum
Timothy Corkum is a seasoned executive with more than two decades of experience in global consumer packaged goods, nicotine innovation, and reduced-risk product development. He most recently served as President of JUUL Labs Canada, where he led the company’s national rollout of its next-generation platform, steering operations through evolving Canadian regulatory frameworks.
Previously, Mr. Corkum held senior commercial leadership roles at Philip Morris International, where he was responsible for driving sales growth, business development, and the execution of reduced-risk product strategies. He also served as Chief Revenue Officer at TAAT Global Alternatives, where he oversaw U.S. retail expansion, sales team leadership, and market penetration into new channels.
Mr. Corkum’s leadership across highly regulated, performance-driven industries brings a proven track record of commercialization, operational execution, and market positioning—critical capabilities as Doseology scales its functional stimulant division and enters new verticals within the Better-for-You space.
Other Business; Early Warning Disclosure
Pursuant to a private placement financing of the Corporation closed on June 12, 2025, Maynard Communication Limited (“Maynard”) acquired 666,666 units of the Corporation (“Units”) and Jesse McRae (“McRae”) acquired 700,000 Units at a price of $0.225 per Unit. Each Unit consisted of one common share of the Corporation (each a “Common Share”) and one Common Share purchase warrant (a “Warrant”) as disclosed in the press release of the Corporation issued on June 12, 2025.
After giving effect to the foregoing subscriptions, Maynard owns an aggregate of 814,000 Common Shares (10.4%) and McRae owns or controls an aggregate of 1,062,964 Common Shares (13.6%) of the 7,836,621 issued and outstanding Common Shares of the Corporation. The Warrants underlying the Units include a term whereby the holder may not exercise if, following exercise of the Warrants, the aggregate Common Shares held by the holder will be greater than 10% of the issued Common Shares of the Corporation.
The Shares acquired by Maynard and McRae are for investment purposes only and they each may acquire additional securities of the Corporation, dispose of some or all of the securities that they now own or control, or may continue to hold their current positions. The acquisition of the Common Shares issued to Maynard and McRae were exempted from securities legislation under Section 2.3 of National Instrument 45-106 – Prospectus and Registration Exemptions and this release is provided pursuant to Part 3 – Early Warning Requirements of National Instrument 62-103. The Common Shares of the Corporation are listed on the Canadian Securities Exchange under the trading symbol "MOOD".
About Doseology Sciences Inc. (CSE: MOOD | PINK: DOSEF | FSE: VU70)
Doseology is a biotech innovation company engineering precision‑ formulated oral stimulants that optimize energy, focus, and cognitive performance. Through rigorous scientific research and advanced delivery technologies, we're pioneering next‑gen performance solutions designed to empower peak performance.
On behalf of the Board of Directors,
Chris Jackson
CEO
Doseology Sciences Inc.
For more information, please contact the Company at:
Email: hello@doseology.com
Website: www.doseology.com
Phone: 604.908.3095
Forward Looking Statements
This press release contains statements that constitute “forward‐looking information” within the meaning of applicable securities laws. Forward‐looking information is often identified by the words “may,” “would,” “could,” “should,” “will,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “expect” or similar expressions. Readers are cautioned that forward‐looking information is not based on historical facts but instead reflects the Company’s management’s expectations, estimates or projections concerning the business of the Company’s future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward‐looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance, or achievements. Among the key factors that could cause actual results to differ materially from those projected in the forward‐looking information are the following: changes in general economic, business and political conditions, including changes in the financial markets; decreases in the prevailing prices for products in the markets that the Company operates in; adverse changes in applicable laws or adverse changes in the application or enforcement of current laws; regulations and enforcement priorities of governmental authorities; compliance with government regulation and related costs; and other risks described in the Company’s prospectus. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward‐looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated, or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward‐looking information except as otherwise required by applicable law. For more information, investors should review the Company’s filings which are available on SEDAR+.
No securities regulatory authority has either approved or disapproved of the contents of this press release. The Company’s securities have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold in the United States, or to or for the account or benefit of any person in the United States, absent registration, or an applicable exemption from the registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities in the United States, or in any other jurisdiction in which such offer, solicitation or sale would be unlawful. The CSE does not accept responsibility for the adequacy or accuracy of this release.